



- (51) **International Patent Classification:**
C07D 403/14 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4192 (2006.01)
- (21) **International Application Number:**
PCT/IB2014/066508
- (22) **International Filing Date:**
2 December 2014 (02.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/IB2013/060596
3 December 2013 (03.12.2013) IB
- (71) **Applicant:** ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).
- (72) **Inventors:** BOSS, Christoph; c/o Actelion Pharmaceutic-
als Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).
BROTSCHI, Christine; c/o Actelion Pharmaceuticals Ltd,
Gewerbestrasse 16, CH-4123 Allschwil (CH). GUDE,
Markus; Grabenring 9, CH-4123 Allschwil (CH).
HEIDMANN, Bibia; c/o Actelion Pharmaceuticals Ltd,
Gewerbestrasse 16, CH-4123 Allschwil (CH). SIFFER-
LEN, Thierry; c/o Actelion Pharmaceuticals Ltd, Gew-
erbestrasse 16, CH-4123 Allschwil (CH). VON
RAUMER, Markus; c/o Actelion Pharmaceuticals Ltd,
Gewerbestrasse 16, CH-4123 Allschwil (CH). WILLI-
AMS, Jodi, T.; c/o Actelion Pharmaceuticals Ltd, Gew-
erbestrasse 16, CH-4123 Allschwil (CH).

- (74) **Agent:** VELKER, Jörg; c/o Actelion Pharmaceuticals Ltd,
Legal Department, Gewerbestrasse 16, CH-4123 Allschwil
(CH).

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*

(54) **Title:** CRYSTALLINE FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AND ITS USE AS OREXIN RECEPTOR ANTAGONISTS

(57) **Abstract:** The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.

